Please activate JavaScript!
Please install Adobe Flash Player, click here for download

Journal of Oral Science & Rehabilitation Issue 01/2015

50 Volume 1 | Issue 1/2015 Journal of Oral Science & Rehabilitation Os teopon tin expres s io n i n ano rgani c bovi ne bo ne 34. Schücklenk U, Ashcroft R. International research ethics. → Bioethics. 2000 Apr;14(2):158–72. 35. American Society of Anesthesiologists. ASA Physical Status Classification System [Internet]. → Schaumburg, Ill.: American Society of Anesthesiologists; [updated 2014 Oct 15; cited 2015 Jul 1]. Available from: http://www.asahq.org/resources/clinical- information/asa-physical-status-classifica tion-system. 36. O’Leary TJ, Drake RB, Naylor JE. The plaque control record. → J Periodontol. 1972 Jan;43(1):38. 37. Wang HL, Katranji A. ABC sinus augmentation classification. → Int J Periodontics Restorative Dent. 2008 Jul-Aug;28(4):383–9. 38. Zinner ID, Small SA. Sinus-lift graft: using the maxillary sinuses to support implants. → J Am Dent Assoc. 1996 Jan;127(1):51–7. 39. Levin L, Herzberg R, Dolev E, Schwartz- Arad D. Smoking and complications of onlay bone grafts and sinus lift operations. → Int J Oral Maxillofac Implants. 2004 May-Jun;19(3):369–73. 40. Galindo-Moreno P, Fauri M, Ávila-Ortiz G, Fernández-Barbero JE, Cabrera-León A, Sánchez-Fernández E. Influence of alcohol and tobacco habits on peri-implant marginal bone loss: a prospective study. → Clin Oral Implants Res. 2005 Oct;16(5):579–86. 41. Galindo-Moreno P, Ávila G, Fernández- Barbero JE, Aguilar M, Sánchez-Fernández E, Cutando A, Wang HL. Evaluation of sinus floor elevation using a composite bone graft mixture. → Clin Oral Implants Res. 2007 Jun;18(3):376–82. 42. Galindo-Moreno P, Ávila G, Fernández- Barbero JE, Mesa F, O’Valle-Ravassa F, Wang HL. Clinical and histologic comparison of two different composite grafts for sinus augmentation: a pilot clinical trial. → Clin Oral Implants Res. 2008 Aug;19(8):755–9. 43. Hallman M, Thor A. Bone substitutes and growth factors as an alternative/complement to autogenous bone for grafting in implant dentistry. → Periodontol 2000. 2008 Jun;47(1):172–92. 44. Wenz B, Oesch B, Horst M. Analysis of the risk of transmitting bovine spongiform encephalopathy through bone grafts derived from bovine bone. → Biomaterials. 2001 Jun;22(12):1599–606. 45. Habibovic P, Yuan H, van der Valk CM, Meijer G, van Blitterswijk CA, de Groot K. 3D microenvironment as essential element for osteoinduction by biomaterials. → Biomaterials. 2005 Jun;26(17):3565–75. 46. Weibrich G, Trettin R, Gnoth SH, Götz H, Duschner H, Wagner W. Bestimmung der Größe der spezifischen Oberfläche von Knochenersatzmaterialien mittels Gasadsorption [Determining the size of the specific surface of bone substitutes with gas adsorption]. → Mund Kiefer Gesichtschir. 2000 May;4(3):148–52. German. 47. Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. → J Bone Miner Res. 2007 Feb;22(2):286–97. 48. McKee MD, Nanci A. Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. Microsc Res Tech. 1996 Feb;33(2):141–64. 49. McKee MD, Nanci A. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. → Connect Tissue Res. 1996 Jan;35(1–4):197–205. 50. McKee MD, Nanci A. Osteopontin deposition in remodeling bone: an osteoblast mediated event. → J Bone Miner Res. 1996 Jun;11(6):873–5. 51. Ganss B, Kim RH, Sodek J. Bone sialoprotein. → Crit Rev Oral Biol Med. 1999;10(1):79–98. 52. Kunii Y, Niwa S, Hagiwara Y, Maeda M, Seitoh T, Suzuki T. The immunohistochemical expression profile of osteopontin in normal human tissues using two site-specific antibodies reveals a wide distribution of positive cells and extensive expression in the central and peripheral nervous systems. → Med Mol Morphol. 2009 Sep;42(3):155–61. 53. Merry K, Dodds R, Littlewood A, Gowen M. Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. → J Cell Sci. 1993 Apr;104(4):1013–20. 54. Bonewald L. Osteocytes as multifunctional cells. → J Musculoskelet Neuronal Interact. 2006 Oct-Dec;6(4):331–3. 55. Holt I, Marshall MJ. Integrin subunit β3 plays a crucial role in the movement of osteoclasts from the periosteum to the bone surface. → J Cell Physiol. 1998 Apr;175(1):1–9. 56. Chellaiah MA, Hruska KA. The integrin αvβ3 and CD44 regulate the actions of osteopontin on osteoclast motility. → Calcif Tissue Int. 2003 Mar;72(3):197–205. 57. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. → J Cell Sci. 1999 Nov;112(22):3985–93. 58. Perrotti V, Nicholls BM, Horton MA, Piattelli A. Human osteoclast formation and activity on a xenogenous bone mineral. → J Biomed Mater Res A. 2009 Jun;90A(1):238–46. 59. Nakamura I, Duong LT, Rodan SB, Rodan GA. Involvement of αvβ3 integrins in osteoclast function. → J Bone Miner Metab. 2007 Nov;25(6):337–44. 60. Reinholt FP, Hultenby K, Oldberg A, Heinegård D. Osteopontin—a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4473–5. 61. Ory S, Brazier H, Pawlak G, Blangy A. Rho GTPases in osteoclasts: orchestrators of podosome arrangement. Eur J Cell Biol. 2008 Sep;87(8-9):469–77. 62. Saad FA, Salih E, Glimcher MJ. Identification of osteopontin phosphorylation sites involved in bone remodeling and inhibition of pathological calcification. J Cell Biochem. 2008 Feb;103(3):852–6. 63. Ek-Rylander B, Andersson G. Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate- resistant acid phosphatase. Exp Cell Res. 2010 Feb;316(3):443–51. 64. Schlegel AK, Donath K. BIO-OSS—a resorbable bone substitute? J Long Term Eff Med Implants. 1998;8(3–4):201–9. References

Pages Overview